Supplemental Figure 6
Supplemental Figure 6. Time spent freezing during a five-minute exposure to TMT. A history of CFA injury increased time spent freezing, and this increase was prevented by administration of HC30031. Data presented as mean value +/- SEM.
## Df Sum Sq Mean Sq F value Pr(>F)
## CFA 1 357 357.1 3.97 0.050885 .
## Drug 1 1898 1898.5 21.10 2.29e-05 ***
## CFA:Drug 1 1091 1091.4 12.13 0.000932 ***
## Residuals 60 5398 90.0
## ---
## Signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
## # A tibble: 2 × 10
## CFA .y. group1 group2 n1 n2 p p.signif p.adj p.adj.signif
## * <fct> <chr> <chr> <chr> <int> <int> <dbl> <chr> <dbl> <chr>
## 1 Naive Perc DMSO HC-030031 16 16 4.65e-1 ns 4.65e-1 ns
## 2 CFA Perc DMSO HC-030031 16 16 1.04e-6 **** 1.04e-6 ****
## # A tibble: 2 × 10
## Drug .y. group1 group2 n1 n2 p p.signif p.adj p.adj.signif
## * <fct> <chr> <chr> <chr> <int> <int> <dbl> <chr> <dbl> <chr>
## 1 DMSO Perc Naive CFA 16 16 9.88e-4 *** 9.88e-4 ***
## 2 HC-0300… Perc Naive CFA 16 16 2.69e-1 ns 2.69e-1 ns
TRPA-1 antagonism reduced freezing in CFA-primed mice, but had no effect on freezing during TMT for naive mice (F1,60 = 12.13, p < 0.001). In the DMSO group, CFA-primed mice froze more than injury-naive mice (p < 0.001). TRPA-1 antagonism blocked the enhancing effect of a history of injury on freezing during TMT presentation. HC30031 treatment reduced freezing among CFA-primed mice (p < 0.001) such that freezing levels were not different from naive mice injected with HC30031 (p = 0.27). There was no effect of HC30031 administration on time spent freezing during TMT for injury-naive mice (p = 0.46).